ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

ANIPNYSE / NASDAQHealthcareSmall cap

$68.55-$0.58 (-0.8%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
23.0x
EV / EBITDA
10.3x
Revenue
$883.4M
Net margin
8.9%
ROCE
7.0%

-12.7% over the last year

ANI Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-5.7%
3M
-11.3%
6M
-16.4%
1Y
-12.7%
5Y
+57.4%

52-week range

Day change -$0.58 (-0.8%) from $69 to $69 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ANIP, bought on each weekday since 2021.

News & filings

What ANI Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -4.6% to 14.5% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • The price is within 1.7% of its 52-week low as of 20 Nov 2026.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.

Read moreShow less

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Sector
Healthcare
Shares outstanding
22.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
23.0x
P/B
3.3x
EV / EBITDA
10.3x
EV / Sales
2.4x
P/S
2.0x
52-week high
$86.03
52-week low
$67.41

Profitability

Operating margin
9.2%
Net margin
8.9%
EBITDA margin
23.5%
ROE
14.5%
ROCE
7.0%
ROA
5.4%
Asset turnover
0.61

Growth

Revenue
$883.4M
Revenue growth, 1Y
43.8%
Revenue CAGR, 3Y
40.8%
Net profit growth, 1Y
-522.9%
Free cash flow
$150.9M

Solvency

Current ratio
2.71
Debt / Equity
1.14
Debt / Assets
0.43
CFO / Net profit
2.36
Cash / Market cap
15.9%

Where the revenue went

Of every $100 of FY2025 revenue, $9 was left as net income.

ANI Pharmaceuticals, Inc. income statement flow, FY2025
ANI Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$341.3M
RevenueGross profit$542.1M
Gross profitResearch and development$51.7M
Gross profitSelling, general and administrative$317.7M
Gross profitOther operating expenses$91.4M
Gross profitOperating income$81.2M
Operating incomePretax income$81.2M
Interest and other incomePretax income$14.6M
Pretax incomeTax and other$17.5M
Pretax incomeNet income$78.3M

Revenue and net profit

Revenue grew 43.8% in FY2025; net profit is the dashed line.

ANI Pharmaceuticals, Inc. revenue and net profit by fiscal year
ANI Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$316.4M-$47.9M
FY2023$486.8M$18.8M
FY2024$614.4M-$18.5M
FY2025$883.4M$78.3M

Cash flows

FY2025: $185.2M from operations, $150.9M free after investment (dashed).

ANI Pharmaceuticals, Inc. operating and free cash flow by fiscal year
ANI Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$31.2M-$47.7M
FY2023$119.0M$100.4M
FY2024$64.0M$47.1M
FY2025$185.2M$150.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$883.4M+43.8%1Y
EBITDA
$207.3M+228.4%1Y
Net profit
$78.3M
Cash from operations
$185.2M+189.3%1Y
Free cash flow
$150.9M+220.6%1Y
Revenue CAGR, 3Y
40.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$883.4M$207.3M$78.3M$150.9M14.5%+43.8%-522.9%

Monthly returns

Month-by-month returns of ANIP across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.4B
Liabilities$899.6M
Equity$540.7M
Paid-in capital$596.0M
Retained earnings-$23.1M
Treasury stock$33.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ANIP highlighted.

P/E against peers

ANIP trades at 23.0x earnings against a peer median of -8.8x.

  1. ANI Pharmaceuticals, Inc. (this company)23.0x

Not shown (no positive earnings and no EV / Sales): Rapport Therapeutics, Inc., SELLAS Life Sciences Group, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ANI Pharmaceuticals, Inc.ANIPthis company$1.8B23.0x3.3x14.5%10.3x
Maravai LifeSciences Holdings, Inc.MRVI$1.8B-14.1x8.7x-61.6%-13.5x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Viridian Therapeutics, Inc.VRDN$1.8B-5.3x3.1x-58.1%-4.9x
Vericel CorporationVCEL$1.8B110.3x5.1x4.7%60.3x
Nuvation Bio Inc.NUVB$1.8B-8.8x5.9x-66.9%-9.0x
Rapport Therapeutics, Inc.RAPP$1.8B—-178.2x-23.0%—
Surgery Partners, Inc.SGRY$1.8B-23.0x1.0x-4.5%9.9x
SELLAS Life Sciences Group, Inc.SLS$1.8B-66.2x25.1x-37.9%-60.4x
Peer median—-8.8x4.1x-30.5%-4.9x

Year-to-date ROI

ANIP since 1 January, against earlier years.

Historical volatility

ANIP's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ANI Pharmaceuticals, Inc. operating margin by fiscal year
ANI Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-8.1%
FY202310.2%
FY20240.4%
FY20259.2%
LineFY2025
Cost of revenueCost Of Revenue$341.3M
Gross profitGross Profit$542.1M
Operating expensesOperating Expense$460.8M
Research and developmentResearch And Development$51.7M
Selling, general and administrativeSelling General And Administration$317.7M
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$91.4M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$91.4M
Total expensesTotal Expenses$802.1M
Pretax incomePretax Income$95.8M

Learn while you research

Academy chapters picked for ANI Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing44% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →